Disclose R&D and manufacturing costs of publicly funded cancer drugs to get coverage

The WHA 2019 transparency resolution called for disclosure of R&D costs and public funding, but implementation has been minimal. Many oncology drugs originate in publicly funded research (NIH, CRUK, national academic centres). The proposal is that public payers require, as a condition of coverage for any oncology drug that received public research funding or tax credits, audited disclosure of clinical development costs, manufacturing cost of goods and public contributions, published in a standard format and used as one input to price negotiations.